Skip To Main Content
Puyaan Singh on Muck Rack

Puyaan Singh

Verified
India
As seen in: Reuters, MSN, MSN UK, ET Healthworld, ETTelecom, MSN Malaysia, Reuters Japan, Terra, USA Today, Yahoo Canada, Yahoo News and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Puyaan

Contact Puyaan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

|
By Puyaan Singh Verified
| MSN Verified
By Puyaan Singh Aug 6 (Reuters) - Eye drugmaker Tarsus Pharmaceuticals said on Thursday it would acquire privately held Alkeus Pharmaceuticals in a cash-and-stock deal worth up to $800 million, adding an experimental oral therapy for a rare inherited retinal disorder with no approved U.S. treatment to its pipeline. The deal includes an upfront payment of about $450 million, comprising $270 million in cash and $180 million in Tarsus common stock, the companies said.
Open in Who Shared View Duplicates (76) Issue with article?

Charles River lifts profit forecast on improving biotech demand

|
By Puyaan Singh Verified
| MSN Verified
By Puyaan Singh Aug 5 (Reuters) - Charles River Laboratories raised its annual profit forecast on Wednesday after the contract drug developer beat quarterly profit and revenue estimates on stronger demand for its drug discovery and development services from biotechs. Shares of the company were up 11.6% at $261.37.
Open in Who Shared View Duplicates (50) Issue with article?

ギリアド、四半期製品売上高が予想上回る 買収費用で赤字

|
By Deena Beasley Verified, Puyaan Singh Verified
| Reuters Japan Verified
米製薬大手ギリアド・サイエンシズのロゴ。2025年11月6日、中国の上海で撮影。REUTERS/Maxim Shemetov [４日 ロイター] - 米製薬大手ギリアド・サイエンシズ(GILD.O)、新しいタブで開きますが４日発表した​第２・四半期決算は、製品売上‌高が８％増加した。抗エイズウイルス（ＨＩＶ）薬が２桁の伸びを示したことがけん引し​た。ただ、一連の企業買収​に関連する費用が響き、損⁠益は赤字となった。 全体の売上高​は１０％増の７８億ドルで、ＬＳＥＧがまとめた市場予想（７４億ドル）​を上回った。ＨＩＶ関連製品、がん治療薬「トロデルビ」、肝疾患治療薬「リブデルジ」​の販売が好調だったとし​た。 ダニエル・オデイ最高経営責任者（ＣＥＯ）は、ＨＩＶ関連‌製品⁠の売上高が１２％増加したとし、２０２６年の基幹事業の売上高見通し引き上げにつながったと述べた。 ギリアドは通​期のＨＩＶ製品売​上高⁠の伸びについても、従来の８％増から９─１０％増に見通しを引き上げ​た。...
Open in Who Shared Issue with article?
See all 2,188 licensed articles (2,231 Total)